Gilead Sciences Inc (NASDAQ:GILD) – Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C

[Business Wire] – Gilead Sciences, Inc. today announced that the company has submitted a New Drug Application to the U.S. Food and Drug Administration for a once-daily fixed-dose combination of the NS5A inhibitor . . . → Read More: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C Similar Articles: Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection Gilead Sciences Inc. (NASDAQ:GILD) – Gilead to seek okay for combo hepatitis C pill in Q1 Gilead Sciences Inc. (NASDAQ:GILD) – European CHMP Adopts Positive Opinion for Gilead Sciences’ Sovaldi® for the Treatment of Chronic Hepatitis C Infection